Singapore markets close in 2 hours 18 minutes
  • Straits Times Index

    3,238.52
    +36.63 (+1.14%)
     
  • Nikkei

    26,911.20
    +251.45 (+0.94%)
     
  • Hang Seng

    20,627.99
    +25.47 (+0.12%)
     
  • FTSE 100

    7,518.35
    +53.55 (+0.72%)
     
  • BTC-USD

    29,942.28
    -470.07 (-1.55%)
     
  • CMC Crypto 200

    672.78
    +430.10 (+177.23%)
     
  • S&P 500

    4,088.85
    +80.84 (+2.02%)
     
  • Dow

    32,654.59
    +431.17 (+1.34%)
     
  • Nasdaq

    11,984.52
    +321.73 (+2.76%)
     
  • Gold

    1,809.90
    -9.00 (-0.49%)
     
  • Crude Oil

    113.04
    +0.64 (+0.57%)
     
  • 10-Yr Bond

    2.9680
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,554.76
    +6.16 (+0.40%)
     
  • Jakarta Composite Index

    6,701.83
    +57.36 (+0.86%)
     
  • PSE Index

    6,713.35
    +118.69 (+1.80%)
     

XCUR Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Exicure, Inc. (XCUR)

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, December 21, 2021--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, for violations of the Securities Exchange Act of 1934. Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immune-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology.

If you suffered a loss due to Exicure, Inc.'s misconduct, click here.

Exicure, Inc. (XCUR) Failed to Disclose Improprieties Associated with its Preclinical Program for the Treatment of Friedreich's Ataxia

According to the complaint, defendants failed to disclose that there had been certain improprieties in Exicure's preclinical program for the treatment of Friedreich's ataxia and that there was a material risk that data from the preclinical program would not support continued clinical development.

On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report ended September 30, 2021. It explained it was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company's XCUR-FXN preclinical program for the treatment of Friedreich's ataxia." On this news, the Company's stock price fell 28%, to close at $1.07 per share on November 16, 2021.

If you acquired shares of Exicure, Inc. (XCUR) securities between March 11, 2021 and November 15, 2021, you have until February 11, 2022, to ask the court to appoint you lead plaintiff for the class.

Representation is on a contingency fee basis. Shareholders pay no fees or costs.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Exicure, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005026/en/

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting